Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02844751 · ClinicalTrials.gov registry record · Phase 2

Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Knee

A Phase 2 study of Osteoarthritis, sponsored by VivaTech International.

Recruiting
Registry status
Phase 2
Development phase
4,000
Enrollment target
1
Study location

NCT02844751: Recruiting Phase 2 study of Osteoarthritis, sponsored by VivaTech International.

NCT02844751 is a Phase 2 study of Osteoarthritis that is actively recruiting participants, run by VivaTech International. The registered enrollment target is 4,000 participants, above the 788-participant average among 135 other Osteoarthritis trials with a reported enrollment target (408% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02844751, a Phase 2 study of Osteoarthritis, is actively recruiting participants, sponsored by VivaTech International.

RECRUITING
Registry status
Phase 2
Development phase
4,000 participants
Enrollment target
1
Study location

Study Summary

This is a prospective open-label clinical study of 50 patients to determine safety and treatment potential of autologous cell therapy for pain and inflammation associated with Osteoarthritis of the knee. Follow-up will consist of a larger sample including 4,000 patients.

Primary Outcome

Knee osteoarthritis outcome score

Conditions Studied

Osteoarthritis

Interventions

  • BIOLOGICAL [StroMed + platelet rich plasma (PRP)]
  • BIOLOGICAL [PRP] platelet rich plasma

Study Locations (1)

Pennsylvania

  • VivaTech International, Inc. - Grove City

Trial Details

FieldValue
Enrollment Target 4,000 participants
Start Date 2015-07
Est. Completion 2026-08
Phase Phase 2
VivaTech International

3 total trials

What NCT02844751 shows while recruiting

NCT02844751 is an interventional study that assigns participants to a tested intervention. Its 4,000 participants enrollment target places it among the larger protocols in the corpus, above the 788-participant average among 135 other Osteoarthritis trials with a reported enrollment target (408% higher).

The record links to 1 condition, with Osteoarthritis appearing as the primary indexed condition, and to 2 interventions - of which [StroMed + platelet rich plasma (PRP)] is the first listed.

NCT02844751 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT02844751 about?

NCT02844751 is a clinical study titled "Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Knee". This is a prospective open-label clinical study of 50 patients to determine safety and treatment potential of autologous cell therapy for pain and inflammation associated with Osteoarthritis of the knee. Follow-up will consist of a larger sample including 4,000 patients.

What is the current status of trial NCT02844751?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 4,000 participants. The study started on 2015-07. Estimated completion is 2026-08.

What conditions does trial NCT02844751 study?

This clinical trial studies the following conditions: Osteoarthritis.

What interventions are being tested in trial NCT02844751?

The interventions under investigation include: [StroMed + platelet rich plasma (PRP)] (BIOLOGICAL), [PRP] platelet rich plasma (BIOLOGICAL).

Who is sponsoring clinical trial NCT02844751?

This trial is sponsored by VivaTech International, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02844751 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Osteoarthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02844751's enrollment target sits among peer trials

4,000 6th of 135 higher than 128 of 135 other Osteoarthritis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Osteoarthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00227253 · 4,000 participants

    Chromosome 18 Clinical Research Center

  • NCT00811148 · 4,000 participants

    Florida Center for Brain Tumor Research

  • NCT00897117 · 4,000 participants

    Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer

  • NCT00899301 · 4,000 participants

    Collecting and Storing Tissue Samples From Women With or Without Breast Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

More recruiting context for NCT02844751

Source: ClinicalTrials.gov NCT02844751, the US trial registry maintained by the National Library of Medicine. NCT02844751 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.